期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尤因肉瘤生物治疗基础研究的现状

Biotherapy of Ewing's sarcoma:Current status of basic research
原文传递
导出
摘要 生物治疗对于预后不良的尤因肉瘤(Ewing’s sarcoma,又称尤文肉瘤)患者具有更好的临床意义,其类型包括基因治疗、免疫治疗、抗血管生成靶向治疗等。尤因肉瘤的基因治疗主要体现在反义核酸技术的应用;免疫治疗主要体现在抗体疗法、T细胞疗法、DC疗法和肿瘤疫苗治疗等方面;抗血管生成治疗主要体现在抑制肿瘤血管的生成,从而抑制肿瘤的生长和迁移。随着研究的深入,发现端粒长度的变化、微粒体谷胱甘肽转移酶1(microsomal glutathione S-transferase 1,MGST1)表达水平、肿瘤转移和多药耐药相关基因的表达以及乳头状瘤病毒结合因子等都有可能成为尤因内瘤预后的判断指标。 Biotherapy is especially beneficial for Ewing＇s sarcoma with bad prognosis.The therapy includes gene therapy,immunotherapy,anti-angiogenesis therapy,etc..Gene therapy mainly refers to the application of antisense nucleic acid technique;immunotherapy refers to antibody therapy,T cell therapy,dendritic cell therapy,and tumor vaccine,etc.;and anti-angiogenesis therapy refers to inhibition of tumor angiogenesis,thus suppressing tumor growth and metastasis.With the deeper understanding of Ewing＇s sarcoma,changes in the telomere length,microsomal glutathione S-transferase 1（MGST1） expression,the expression of tumor metastasis and multi-drug resistance genes,and papillomavirus binding factor might serve as novel predictors for the prognosis of Ewing＇s sarcoma.
作者 王洪伟 李长青 周跃
机构地区 第三军医大学附属新桥医院骨科
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2010年第3期349-353,共5页 Chinese Journal of Cancer Biotherapy
关键词 尤因肉瘤 生物治疗 生物标志 Ewing＇s sarcoma biotherapy basic research
分类号 R738.1 [医药卫生—肿瘤]
  • 相关文献

参考文献37

  • 1van den Berg H, Kroon HM, Slaar A, Hogeudoorn P. Incidence of biopsy-proven bone tumors in children: A report based on the Dutch pathology registration " PALGA "' [ J ]. J Pediatr Orthop, 2008, 28 ( 1 ) : 29-35.
  • 2Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing' s sarcoma patients over the past 3 decades : Surveillance epidemiology and end results data [J]. J Pediatr Hematol Oncol, 2008, 30(6) : 425-430.
  • 3Martins AS, Ordonez JL, Garcia-Sanchez A, Herrero D, Sevillano V, Osuna D, et al. A pivotal role for heat shock protein 90 in Ewing's sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: In vitro and in vivo study [ J]. Cancer Res, 2008, 68(15): 6260-6270.
  • 4Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein [J]. J Biol Chem, 2009, 284(14): 9074-9082.
  • 5Anumanthan G, Halder SK, Friedman DB, Dana PK. Oncogenic serine-threonine kinase receptor-associated protein modulates the function of Ewing' s sarcoma protein through a novel mechanism [J]. Cancer Res, 2006, 66(22): 10824-10832.
  • 6Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing' s sarcoma [ J ]. Int J Cancer, 2006, 119 (5) : 1039-1046.
  • 7Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-1 receptor is required for EWS/FLI-1 transformation of fibroblasts [J]. J Biol Chem, 1997, 272(49): 30822 -30827.
  • 8Le Roith D, Helman L. The new kid on the block (ade) of the IGF-1 receptor [J]. Cancer Cell, 2004, 5(3): 201-202.
  • 9Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, et al. Preclinical in vivo study of new insulin-like growth factor- I receptor--specific inhibitor in Ewing' s sarcoma [ J ]. Clin Cancer Res, 2007, 13(4) : 1322-1330.
  • 10Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models [ J]. Cytokine/Growth Factor Rev, 2005, 16(4-5) : 407-420.

二级参考文献77

  • 1寿成超.抗血管生成与肿瘤生物治疗[J].中国肿瘤生物治疗杂志,2006,13(6):401-403. 被引量：3
  • 2章卫平,曹雪涛,张明徽,黄欣,朱学军,叶天星.GM-CSF重组腺病毒扩增的骨髓树突状细胞体外经肿瘤抗原刺激后诱导抗肿瘤免疫应答[J].中国免疫学杂志,1997,13(1):29-33. 被引量：14
  • 3Finn OJ. Human tumor immunology at the molecular divide [J]. J Immunol, 2007, 178(5) : 2615-2616.
  • 4Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery [J]. Cancer Treat Res, 2005, 123: 89-111.
  • 5Wang Q, Ornstein M, Kaufman HL. Imaging the immune response to monitor tumor immunotherapy [ J ]. Expert Rev Vaccines, 2009, 8(10) : 1427-1437.
  • 6Ji H, Houghton AM, Mariani TJ, et al. K-ras activation generates an inflammatory response in lung tumors [ J]. Oncogene, 2006, 25(14) : 2105-2112.
  • 7Eli Gilboa. DC-based cancer vaccines[J]. J Clin Invest, 2007, 117(5) : 1195-1203.
  • 8Teicher BA. Transforming growth factor-beta and the immune response to malignant disease [J]. Clin Cancer Res, 2007, 13 (21) : 6247-6251.
  • 9Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer [J]. Curr Cancer Drug Tar, 2007, 7(1): 31-40.
  • 10Chikamatsu K, Sakakura K, Whiteside TL, et al. Relationships between regulatory T cells and CD8^ + effector populations in patients with squamous cell carcinoma of the head and neck [J].Head Neck, 2007, 29(2) : 120-127.

共引文献41

中国肿瘤生物治疗杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部